Evaluate Bioequivalence of Micafungin (50mg/Vial)
Study Details
Study Description
Brief Summary
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of micafungin (50 mg/vial) after intravenous infusion of 50 mg micafungin in healthy volunteers under fasting conditions
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Micafungin (Product name:Myfungin) Single dose micafungin 50mg |
Drug: Micafungin
Pharmacokinetic study under fasting conditions
|
| Active Comparator: Micafungin (Product name:Mycamine) Single dose micafungin 50mg |
Drug: Micafungin
Pharmacokinetic study under fasting conditions
|
Outcome Measures
Primary Outcome Measures
- Peak plasma concentration (Cmax) [0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose]
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) [0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose]
- Area under the concentration-time curve from time zero to infinity (AUC 0-∞) [0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose]
- Ratio of area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) to Area under the concentration-time curve from time zero to infinity (AUC 0-∞) [0 (pre-dose), 20 and 40 minutes, and 5, 15, 30 minutes, 1, 2, 3, 5, 7, 11, 23, 35,47 and 59 hours post dose]
Calculate the ratio between Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) and Area under the concentration-time curve from time zero to infinity (AUC 0-∞). It require no less than 0.8.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit.
-
Body mass index (BMI) between 18 and 27 kg/m2 (not inclusive) at the screening visit.
-
Acceptable medical history and physical examination including:
-
no particular clinically significant abnormalities in ECG results within six months prior to Period I dosing.
-
no particular clinical significance in general disease history within two months prior to Period I dosing.
-
Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes AST (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride (TG).
-
Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets.
-
Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.
-
Female of childbearing potential practicing an acceptable method of birth control for the duration of the study.
-
Have signed the written informed consent to participate in the study.
Exclusion Criteria:
-
A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, urinary tract, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease.
-
A clinically significant illness or surgery within four weeks prior to Period I dosing.
-
History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years.
-
History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant.
-
Known or suspected history of drug abuse within lifetime.
-
History of alcohol addiction or abuse within last five years or use of more than 7 units of alcohol per week within two weeks prior to dosing. (1 unit of alcohol = 10 g of alcohol or about 350 mL of beer or about 83 mL of red wine or about 30 mL of beverage containing 40% (v/v) alcohol).
-
History of allergic response(s) to palonosetron or any other related drugs.
-
Evidence of chronic or acute infectious diseases.
-
Positive result for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV).
-
Female subjects demonstrating a positive pregnancy screen prior to the study.
-
Female subjects who are currently breastfeeding.
-
Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks prior to Period I dosing. Examples of inducers include: piperidines, carbamazepine, dexamethasone and rifampin. Examples of inhibitors include: cimetidine, diphenhydramine, fluvastatin, methadone and ranitidine.
-
Taking any prescription medications within four weeks or any nonprescription medications (excluding flu vaccination) within two weeks prior to Period I dosing.
-
Use of any investigational drug within four weeks prior to Period I dosing.
-
Use of any COVID-19 vaccine within seven days prior to Period I dosing.
-
Donating more than 250 mL of blood within two months prior to Period I dosing or donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing.
-
Any other medical reason as determined by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Taichung Veterans General Hospital | Taichung | Taiwan |
Sponsors and Collaborators
- Yung Shin Pharm. Ind. Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- YSP-RNH3001-01